Compare Ginkgo Bioworks Holdings Inc (DNA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Sibanye Stillwater Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Sibanye Stillwater Ltd trades at $10.64 (market cap $7.54B). The key difference: Sibanye Stillwater Ltd is far larger — about 14.9× Ginkgo Bioworks Holdings Inc's market cap, and Sibanye Stillwater Ltd pays a 2.93% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SBSW | |
|---|---|---|
Market Cap | $505.73M | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $16.14 | $21.12 |
52-Week Low | $5.48 | $7.27 |
Enterprise Value | $607.68M | $9.19B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Sibanye Stillwater (SBSW) trades at $10.77, up 0.94% with a bullish technical signal. Despite negative profitability metrics, the stock shows attractive valuation with P/E of 4.76 and P/S of 0.94. Recent earnings misses contrast with improved cash flow projections for 2025. Analyst consensus is mixed with 42.9% buy ratings and $14.25 price target, suggesting 32% upside potential.
The stock presents a value opportunity with deep undervaluation but carries significant execution risk. Key catalysts include debt reduction initiatives and commodity price recovery, while persistent negative margins and volatile earnings remain concerns. Institutional sentiment leans cautiously optimistic given the substantial discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
